CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 372 enrolled
Drug / intervention
Placebo +3 moredrug
Likely dose
Pregabalin 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00394901
NCT00394901Phase 3Completed
CompareCT.gov

A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin In The Treatment Of Postherpetic Neuralgia

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Nov 2, 2006·Updated Feb 9, 2021

In Brief

A Phase 3 clinical trial evaluating Placebo and Pregabalin for Neuralgia, Postherpetic. Completed, enrolled 372 participants across 39 sites.

Detailed Summary

The purpose of this study is to evaluate efficacy and safety of pregabalin in the treatment of postherpetic neuralgia in a dose-ranging manner.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuralgia, Postherpetic
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2, 2006
Enrollment StartSep 1, 2006
Primary CompletionNov 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.7 years ago

Interventions

Placebodrug

placebo, oral administration for 13 weeks (1 week titration and 12-week fixed dose).

Pregabalindrug

Pregabalin 150mg/day (75mg BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).

Pregabalindrug

Pregabalin 300mg/day (150mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).

Pregabalindrug

Pregabalin 600 mg/day (300 mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).